Isothioureas make a class of amphiphilic compounds carrying a highly basic isothiourea group of pK a > 10, hence, at physiological pH they exist in protonated (cation) form, what is of key importance for molecular recognition of specific receptors. Recently, we have found that a number of S-pentabromobenzylisothiourea derivatives show substantial cytotoxicity toward human glioblastoma cells as well as human leukemia and adenocarcinoma cell lines [1] [2] [3] . Not very much attention was devoted to heterocyclic isotiourea derivatives. Here we report the synthesis and pharmacological in vitro properties of new seven (benzimidazol-2-yl)methyl and 5,6-dichlorobenzimidazol-2-yl)methyl isothiourea derivatives. The compounds were obtained by the synthesis from respective 2-chloromethyl benzimidazoles with variously substituted N(N')-thioureas. Beside the basic physicochemical characteristics (H-NMR, UV, elemental analysis) of the new compounds their logP's values, important for drug distribution and interaction, were determined. Pharmacological (anticancer) activity of the compounds was evaluated on the basis of apoptosis induction in human acute myelogenous leukemia cell line (KG-1). The cells used in experiments were in exponential growth phase and were incubated with tested compounds for 24 and 48 h. Evaluation of apoptotic effects on KG-1 cells was carried out using different flow cytometric methods. The tested compounds induced structure related apoptotic effects in KG-1 cells. The apoptotic effects were time-and dose-dependent. Additionally, mitochondrial membrane potential decrease was observed. These results suggest that examined compounds exhibit promising anticancer activity.
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